利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.085 秒)

    Substituted heterocyclic compounds and methods of use
    32.
    发明授权
    Substituted heterocyclic compounds and methods of use 失效
    取代的杂环化合物及其使用方法

    公开(公告)号：US07429594B2

    公开(公告)日：2008-09-30

    申请号：US10923067

    申请日：2004-08-20

    申请人： Longbin Liu ,  Patricia Lopez ,  Manoj Bajpai ,  Aaron C. Siegmund

    发明人： Longbin Liu ,  Patricia Lopez ,  Manoj Bajpai ,  Aaron C. Siegmund

    IPC分类号： C07D401/04 ,  A61K31/519

    CPC分类号： C07D487/04 ,  C07D401/04

    摘要： The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

    摘要翻译： 本发明涉及具有通式的化合物或其药学上可接受的盐，其中R 1是饱和或不饱和的5-，6-或7-元环，其含有0,1,2或 3个选自N，O和S的原子，其中环可以与苯并稠合，并被0,1或2个氧代基取代，并且其中R 1是另外被取代的; R 2是取代的C 1-6烷基。 还包括预防或治疗炎症，类风湿性关节炎，斑节病，骨质疏松症，多发性骨髓瘤，葡萄膜炎，急性或慢性骨髓性白血病，胰腺β细胞破坏，骨关节炎，类风湿性脊椎炎，痛风性关节炎，炎性肠病，成人呼吸 窘迫综合征（ARDS），牛皮癣，克罗恩病，过敏性鼻炎，溃疡性结肠炎，过敏反应，接触性皮炎，哮喘，肌肉退化，恶病质，赖特综合征，I型糖尿病，II型糖尿病，骨吸收疾病，移植物抗宿主反应， 阿尔茨海默病，中风，心肌梗死，缺血再灌注损伤，动脉粥样硬化，脑外伤，多发性硬化，脑疟疾，败血症，败血性休克，中毒性休克综合征，发热，HIV-1，HIV-2，HIV-3，巨细胞病毒引起的肌痛 （CMV），流感，腺病毒，哺乳动物中的疱疹病毒或带状疱疹感染，包括给予有效量的化合物d 以上所述。

    Substituted heterocyclic compounds and methods of use
    33.
    发明授权
    Substituted heterocyclic compounds and methods of use 失效

    公开(公告)号：US07049318B2

    公开(公告)日：2006-05-23

    申请号：US10897884

    申请日：2004-07-23

    申请人： Celia Dominguez ,  Timothy Scot Harvey ,  Longbin Liu ,  Aaron Siegmund

    发明人： Celia Dominguez ,  Timothy Scot Harvey ,  Longbin Liu ,  Aaron Siegmund

    IPC分类号： A61K31/505

    CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D487/04

    摘要： The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

    Substituted heterocyclic compounds and methods of use
    34.
    发明申请
    Substituted heterocyclic compounds and methods of use 失效
    取代的杂环化合物及其使用方法

    公开(公告)号：US20050020592A1

    公开(公告)日：2005-01-27

    申请号：US10897884

    申请日：2004-07-23

    申请人： Celia Dominguez ,  Timothy Harvey ,  Longbin Liu ,  Aaron Siegmund

    发明人： Celia Dominguez ,  Timothy Harvey ,  Longbin Liu ,  Aaron Siegmund

    IPC分类号： A61P29/00 ,  C07D401/04 ,  C07D401/14 ,  C07D487/04 ,  A61K31/53 ,  A61K31/4965 ,  A61K31/5377 ,  C07

    CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D487/04

    摘要： The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

    摘要翻译： 本发明涉及具有通式的化合物或其药学上可接受的盐，其中R 1是饱和或不饱和的含有0,1,2或3个选自N， ，0和S，其中所述环可以与苯并稠合，并且被0,1或2个氧代基取代，并且其中R 1另外被取代; R 2是取代的C 1-6烷基。 还包括预防或治疗炎症，类风湿性关节炎，斑节病，骨质疏松症，多发性骨髓瘤，葡萄膜炎，急性或慢性骨髓性白血病，胰腺β细胞破坏，骨关节炎，类风湿性脊椎炎，痛风性关节炎，炎性肠病，成人呼吸 窘迫综合征（ARDS），牛皮癣，克罗恩病，过敏性鼻炎，溃疡性结肠炎，过敏反应，接触性皮炎，哮喘，肌肉退化，恶病质，赖特综合征，I型糖尿病，II型糖尿病，骨吸收疾病，移植物抗宿主反应， 阿尔茨海默病，中风，心肌梗死，缺血再灌注损伤，动脉粥样硬化，脑外伤，多发性硬化，脑疟疾，败血症，败血性休克，中毒性休克综合征，发热，HIV-1，HIV-2，HIV-3，巨细胞病毒引起的肌痛 （CMV），流感，腺病毒，哺乳动物中的疱疹病毒或带状疱疹感染，包括给予有效量的化合物d 以上所述。

    Recombinant human interferon-like proteins
    37.
    发明授权
    Recombinant human interferon-like proteins 有权
    重组人干扰素样蛋白

    公开(公告)号：US07868151B2

    公开(公告)日：2011-01-11

    申请号：US12555762

    申请日：2009-09-08

    申请人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    发明人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    IPC分类号： C07H21/04 ,  A61K38/15 ,  C07K14/00 ,  C12P21/02

    CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555

    摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

    摘要翻译： 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人类干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

    RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS
    38.
    发明申请
    RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS 有权
    重组人类干扰素蛋白

    公开(公告)号：US20080312148A1

    公开(公告)日：2008-12-18

    申请号：US11764786

    申请日：2007-06-18

    申请人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    发明人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Jing Xu ,  Rui Zhang ,  Ling Wang ,  Yong Du ,  Longbin Liu

    IPC分类号： A61K38/21 ,  A61P35/00 ,  C07K14/00 ,  C12N1/19 ,  C12N1/21 ,  C12N15/11 ,  C12N15/63 ,  C12N5/10

    CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555

    摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

    摘要翻译： 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

    Recombinant human interferon-like proteins
    40.
    发明授权
    Recombinant human interferon-like proteins 有权
    重组人干扰素样蛋白

    公开(公告)号：US08425895B2

    公开(公告)日：2013-04-23

    申请号：US12665682

    申请日：2007-06-22

    申请人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

    发明人： Haitao Wang ,  Chunsheng Mao ,  Jizhi Li ,  Ling Wang ,  Yong Du ,  Longbin Liu ,  Jing Xu ,  Rui Zhang

    IPC分类号： A61K38/21 ,  C07K14/00 ,  C08H1/02 ,  C12P21/04 ,  C07H21/04 ,  A61K38/00

    CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555

    摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

    摘要翻译： 本申请涉及重组人类干扰素样蛋白。 在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。